Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease
Open Access
- 8 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (9), 1978-1986
- https://doi.org/10.1182/bloodadvances.2019001384
Abstract
Sickle cell disease (SCD) patients are at a four- to 100-fold increased risk for thrombosis compared with the general population, although the mechanisms and risk factors are not clear. We investigated the incidence and predictors for thrombosis in a retrospective, longitudinal cohort of 1193 pediatric and adult SCD patients treated at our institution between January 2008 and December 2017. SCD diagnosis and thrombotic complications were identified using International Classification of Diseases coding and verified through medical chart review. Clinical and laboratory data were extracted from the medical records. With a median follow-up of 6.4 years, 208 (17.4%) SCD patients experienced 352 thrombotic events (64 strokes, 288 venous thromboembolisms [VTE]). Risk factors for stroke included older age and HbSS/Sβ0-genotype and a lower hemoglobin (Hb) F% in the subset of HbSS/Sβ0-genotype patients (P < .05). VTE risk was independently associated with lower estimated glomerular filtration rate, hydroxyurea (HU) use, HbSS/Sβ0 genotype, and higher white blood cell (WBC) counts and Hb (P ≤ .03). Two thrombomodulin gene variants previously associated with thrombosis in the general African American population, THBD rs2567617 (minor allele frequency [MAF] 0.25; odds ratio [OR], 1.5; P = .049) and THBD rs1998081 (MAF, 0.24; OR, 1.5; P = .059), were associated with thrombosis in this cohort. In summary, thrombotic complications are common, and several traditional and SCD-specific risk factors are associated with thrombotic risk. Future studies integrating clinical, laboratory, and genetic risk factors may improve our understanding of thrombosis and guide intervention practices in SCD.Keywords
This publication has 55 references indexed in Scilit:
- Pulmonary embolism in sickle cell disease: a case–control studyJournal of Thrombosis and Haemostasis, 2012
- The epidemiology, evaluation and treatment of stroke in adults with sickle cell diseaseExpert Review of Hematology, 2011
- Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell diseaseBlood, 2011
- Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell diseaseAmerican Journal of Hematology, 2010
- Chronic kidney disease and venous thromboembolism: epidemiology and mechanismsCurrent Opinion in Pulmonary Medicine, 2009
- Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsAmerican Journal of Hematology, 2009
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2009
- Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemiaBlood, 2009
- Hypercoagulability in Sickle Cell Disease: New Approaches to an Old ProblemHematology, 2007
- Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?Journal of Thrombosis and Haemostasis, 2006